Come ottenerlo

Scrivici su WhatsApp Chiedi agli esperti

2001 November Natural killer cell‐based immunotherapy in cancer: current insights and future prospects. As our understanding of the molecular mechanisms governing natural killer (NK) cell activity increases, their potential in cancer immunotherapy is growing increasingly prominent. LEGGI

2001 November The biology of human natural killer-cell subsets. Human natural killer (NK) cells comprise ≈15% of all circulating lymphocytes. LEGGI

2001 November A central role for deathreceptor-mediated apoptosisin the rejection of tumorsby NK cells. NK cells provide a line of defense against tumors and virus-infected cells that have lost the expression of one or more MHC class I isoforms. LEGGI

2006 May Genetically re-engineered K562 cells significantly expand and functionallyactivate cord blood natural killer cells:Potential for adoptive cellular immunotherapy. Natural killer (NK) cells play a significant role in reducing relapse in patients with hematological malignancies after allogeneic stem cell transplantation, but NK cell number and naturally occurring inhibitory signals limit their capability. LEGGI

2008 May Correlation between NK function and response to trastuzumab in metastaticbreast cancer patients Trastuzumab is a monoclonal antibody selectively directed against Her2 and approved for the treatment of Her2 overexpressing breast cancer patients. LEGGI

2008 June Umbilical cord blood transplantation: basic biologyand clinical challenges to immune reconstitution. Allogeneic stem cell transplantation has continued to evolve as a common procedure for the treatment of hematological malignancies and bone marrow failure. LEGGI

2008 July CD16+ CD56- NK cells in the peripheralblood of cord blood transplant recipients:a unique subset of NK cells possiblyassociated with graft-versus-leukemiaeffect. A marked increase in CD16+ CD56- NK cells in the peripheral blood (PB) was observed in a cord blood transplant (CBT) recipient with refractory acute myeloid leukaemia (AML) in association with attaining molecular remission. LEGGI

2009 April Fully functional NK cells after unrelatedcord blood transplantation. Promising results of umbilical cord blood transplantation (UCBT) from unrelated donors have been reported in patients with hematologic disorders. LEGGI

2013 January GMP-Compliant, Large-Scale Expanded Allogeneic Natural Killer Cells Have Potent Cytolytic Activity against Cancer CellsIn Vitro and In Vivo Ex vivo-expanded, allogeneic natural killer (NK) cells can be used for the treatment of various types of cancer. LEGGI

2012 July Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy. Natural killer (NK) cells are part of the innate immune system and are an alluring option for immunotherapy due to their ability to kill infected cells or cancer cells without prior sensitization. LEGGI

2013 November Reduction of the CD16−CD56 bright NKCell Subset Precedes NK Cell Dysfunctionin Prostate Cancer Natural cytotoxicity, mediated by natural killer (NK) cells plays an important role in the inhibition and elimination of malignant tumor cells. LEGGI

2014 June Positive and negative regulation byNK cells in cancer. Our understanding of NK biology has expanded immensely since the initial discovery of natural killer cells in 1975. LEGGI

2015 November Advances in clinical NK cell studies:Donor selection, manufacturing andquality control. Natural killer (NK) cells are increasingly used in clinical studies in order to treat patients with various malignancies. LEGGI

2016 January Cord Blood as a Source of Natural KillerCells ord blood (CB) offers several unique advantages as a graft source for hematopoietic stem cell transplantation (HSCT). LEGGI

2016 November Manufacturing Natural Killer Cells as Medicinal Products. Natural Killer (NK) cells are innate lymphoid cells (ILC) with cytotoxic and regulatory properties. LEGGI

2017 February Genetically re-engineered K562 cells significantly expand and functionallyactivate cord blood natural killer cells:Potential for adoptive cellularimmunotherapy Natural killer (NK) cells play a significant role in reducing relapse in patients with hematological malignancies after allogeneic stem cell transplantation, but NK cell number and naturally occurring inhibitory signals limit their capability. LEGGI

2017 February Antibody‐dependent cell cytotoxicity:Immunotherapy strategies enhancing effectorNK cells. Antibody‐dependent cellular cytotoxicity (ADCC) is a set of mechanisms that target cells coated with IgG antibodies of the proper subclasses (IgG1 in the human) to be the prey of cell‐to‐cell cytolysis executed by immune cells expressing FcRIIIA (CD16A). LEGGI

2017 March Umbilical Cord Blood Natural Killer Cells,Their Characteristics, and PotentialClinical Applications. Natural killer (NK) cells are lymphocytes of the innate immune system able to kill different targets such as cancer cells and virally infected cells without prior activation making then attractive candidates for cancer immunotherapy. LEGGI

2017 April Shaping of Natural Killer CellAntitumor Activity by Ex Vivo Cultivation. Natural killer (NK) cells are a promising tool for the use in adoptive immunotherapy, since they efficiently recognize and kill tumor cells. LEGGI

2017 May Characterization of cord blood naturalkiller cells: implications for transplantationand neonatal infections. The role of natural killer (NK) cells in hematopoietic stem cell transplantation and in the control of neonatal infections is not yet clear. Donor-versus-recipient NK cell alloreactivity was found to improve outcome in some settings of hematopoietic stem cell transplantation. LEGGI

2017 May Fully automated expansion andactivation of clinical-grade natural killercells for adoptive immunotherapy. The role of natural killer (NK) cells in hematopoietic stem cell transplantation and in the control of neonatal infections is not yet clear. LEGGI

2017 May Leveraging natural killer cellsfor cancer immunotherapy. Natural killer (NK) cells are potent antitumor effector cells of the innate immune system. LEGGI

2017 July Natural Killer Cell-Based Cancer Immunotherapies: From Immune Evasionto Promising Targeted CellularTherapies. Immunotherapies based on natural killer (NK) cells are among the most promising therapies under development for the treatment of so far incurable forms of leukemia and other types of cancer. LEGGI

2017 August NK cell-based cancer immunotherapy:from basic biology to clinicalapplication. atural killer (NK) cells, which recognize and kill target cells independent of antigen specificity and major histocompatibility complex (MHC) matching, play pivotal roles in immune defence against tumors. However, tumor cells often acquire the ability to escape NK cell-mediated immune surveillance. LEGGI

2017 April Shaping of Natural Killer Cell Anti -tumor Activity by Ex Vivo Cultivation Natural killer (NK) cells are a promising tool for the use in adoptive immunotherapy, since they efficiently recognize and kill tumor cells. LEGGI

2018 Febuary Anticancer cellular immunotherapiesderived from umbilical cord blood. he lack of highly effective drugs in many malignancies has prompted scientific interest in the development of alternative treatment strategies. LEGGI

2018 February Cord blood NK cells engineered to expressIL-15 and a CD19-targeted CARshow long-term persistence and potentantitumor activity. Chimeric antigen receptors (CARs) have been used to redirect the specificity of autologous T cells against leukemia and lymphoma with promising clinical results. LEGGI

2018 April Ex vivo expansion of humanperipheral blood natural killer cellsand cytotoxic T lymphocytes fromlung cancer patients. Lung cancer is the most common type of cancer with the highest cancer-associated mortality rates worldwide, as well as in Vietnam. LEGGI

2018 April Natural killer-dendritic cell cross-talk in cancer immunotherapy. Natural killer (NK) cells and dendritic cells (DCs), two important components of the immune system, can exchange bidirectional activating signals in a positive feedback. LEGGI

2018 October Antigen presenting cell-mediatedexpansion of human umbilical cord blood yieldslog-scale expansion of natural killercells with anti-myeloma activity. Natural killer (NK) cells are important mediators of anti-tumor immunity and are active against several hematologic malignancies, including multiple myeloma (MM). LEGGI

2018 December Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediatedcytotoxicity against pancreaticcancer cell lines with low humanepidermal growth factor-likereceptor 2 expression. Because human epidermal growth factor-like receptor (HER) 2 is expressed on the surface of human pancreatic carcinoma cells to varying degrees, trastuzumab, an anti-HER2 monoclonal antibody (mAb), is expected to exert antibody-dependent, natural killer (NK) cell-mediated cytotoxicity (ADCC) against the cells. LEGGI

Contenuti scientifici revisionati dal Comitato Scientifico di Bioscience Institute. · Ultimo aggiornamento 2025-05-05

Le informazioni in questa pagina hanno scopo divulgativo e non sostituiscono il consulto con un medico.

Questa pagina in altre lingue: English 中文

Studi Clinici

Richiedi informazioni

Sangue e tessuto cordonale alla nascita, tessuto adiposo a ogni età: crioconservazione nella criobanca GMP di San Marino, dal 2008.

Studi Clinici

Richiedi informazioni

Sangue e tessuto cordonale alla nascita, tessuto adiposo a ogni età: crioconservazione nella criobanca GMP di San Marino, dal 2008.

Seguici sui social